Compare BRBS & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRBS | ETON |
|---|---|---|
| Founded | 1893 | 2017 |
| Country | United States | United States |
| Employees | 302 | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.9M | 872.7M |
| IPO Year | 2015 | 2018 |
| Metric | BRBS | ETON |
|---|---|---|
| Price | $3.57 | $35.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | 295.6K | ★ 337.1K |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 24.78% | N/A |
| EPS Growth | ★ 135.48 | N/A |
| EPS | 0.01 | ★ 0.05 |
| Revenue | ★ $111,284,000.00 | $79,950,000.00 |
| Revenue This Year | N/A | $40.90 |
| Revenue Next Year | N/A | $47.23 |
| P/E Ratio | ★ $349.00 | $696.40 |
| Revenue Growth | ★ 123.99 | 104.94 |
| 52 Week Low | $3.23 | $13.51 |
| 52 Week High | $4.79 | $35.66 |
| Indicator | BRBS | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 72.36 | 69.61 |
| Support Level | $3.24 | $15.77 |
| Resistance Level | $3.71 | $35.66 |
| Average True Range (ATR) | 0.07 | 1.64 |
| MACD | 0.04 | 0.30 |
| Stochastic Oscillator | 89.02 | 89.31 |
Blue Ridge Bankshares Inc is a United States-based company engaged in offering commercial and consumer banking and financial services through its wholly-owned bank subsidiary and its non-bank financial services affiliates. The bank offers services such as checking accounts, savings accounts, money market accounts, cash management accounts, commercial and industrial loans, residential mortgages, commercial mortgages, home equity loans, consumer installment loans, investment accounts, insurance, and others. It generates the majority of its revenue from commercial banking.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.